For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Scope of the Report:
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The worldwide market for Hyperimmune Globulins is expected to grow at a CAGR of roughly 11.6% over the next five years, will reach 140 million US$ in 2024, from 82 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Hyperimmune Globulins in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- CSL Behring
- Grifols
- Biotest
- Kedrion
- CBPO
- Emergent (Cangene)
- Kamada
- CNBG
- Hualan Bio
- Shanghai RAAS
- Sichuan Yuanda Shuyang
- ADMA Biologics
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Hepatitis B Immunoglobulins
- Rabies Immunoglobulins
- Tetanus Immunoglobulins
- Rho(D) Immunoglobulins
- Others
Market Segment by Applications, can be divided into
- Government Institutions
- Private Sector
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hyperimmune Globulins product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hyperimmune Globulins, with price, sales, revenue and global market share of Hyperimmune Globulins in 2017 and 2018.
Chapter 3, the Hyperimmune Globulins competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hyperimmune Globulins breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Hyperimmune Globulins market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Hyperimmune Globulins sales channel, distributors, customers, research findings and conclusion, appendix and data source.